Table 2 Mean reduction in monthly migraine headache days, 50 % response rates, and improvement in MSQ-RFR scores among patients who did not benefit from individual preventive medications
Preventive medication | PBO | GMB 120 mg | p value |
|---|---|---|---|
Topiramate | |||
LS mean change from baseline in monthly migraine headache days across months 1–3 (SE) | -1.0 (0.4) | -4.2 (0.4) | < 0.0001 |
≥ 50 % reduction in monthly migraine headache days across months 1–3, % (SE) | 14.7 (2.2) | 37.8 (3.0) | < 0.0001 |
LS mean change from baseline in MSQ-RFR at month 3 (SE) | + 10.4 (1.9) | + 22.5 (1.9) | < 0.0001 |
Amitriptyline | |||
LS mean change from baseline in monthly migraine headache days across months 1–3 (SE) | -1.2 (0.5) | -4.3 (0.5) | < 0.0001 |
≥ 50 % reduction in monthly migraine headache days across months 1–3, % (SE) | 13.9 (2.4) | 37.4 (3.3) | < 0.0001 |
LS mean change from baseline in MSQ-RFR at month 3 (SE) | + 10.4 (2.0) | + 23.6 (2.1) | < 0.0001 |
Propranolol | |||
LS mean change from baseline in monthly migraine headache days across months 1–3 (SE) | -1.7 (0.6) | -4.3 (0.6) | 0.0005 |
≥ 50 % reduction in monthly migraine headache days across months 1–3, % (SE) | 14.9 (3.3) | 34.5 (4.3) | 0.0008 |
LS mean change from baseline in MSQ-RFR at month 3 (SE) | + 10.4 (2.8) | + 22.9 (2.7) | 0.0001 |
Valproate or divalproex | |||
LS mean change from baseline in monthly migraine headache days across months 1–3 (SE) | -0.4 (0.5) | -3.6 (0.5) | < 0.0001 |
≥ 50 % reduction in monthly migraine headache days across months 1–3, % (SE) | 10.6 (3.1) | 33.8 (4.7) | 0.0002 |
LS mean change from baseline in MSQ-RFR at month 3 (SE) | + 6.1 (2.2) | + 17.0 (2.3) | < 0.0001 |
Onabotulinum toxin A | |||
LS mean change from baseline in monthly migraine headache days across months 1–3 (SE) | -1.5 (1.0) | -6.3 (0.9) | < 0.0001 |
≥ 50 % reduction in monthly migraine headache days across months 1–3, % (SE) | 9.9 (3.9) | 38.7 (5.7) | 0.0008 |
LS mean change from baseline in MSQ-RFR at month 3 (SE) | + 5.4 (5.4) | + 24.0 (5.2) | < 0.0001 |
Metoprolol | |||
LS mean change from baseline in monthly migraine headache days across months 1–3 (SE) | -0.3 (0.9) | -3.0 (0.9) | 0.0023 |
≥ 50 % reduction in monthly migraine headache days across months 1–3, % (SE) | 14.7 (4.1) | 33.1 (5.4) | 0.0112 |
LS mean change from baseline in MSQ-RFR at month 3 (SE) | + 5.8 (3.4) | + 16.5 (3.4) | 0.0025 |